Detail akcie GSK Rg online

Business Summary: GSK plc is a global biopharma company. The Company’s segments include Commercial Operations and Research and Development. Its portfolio and pipeline are focused on developing medicines and vaccines in four core therapeutic areas, which are the areas of human health it focuses on to prevent and treat disease: respiratory, immunology and inflammation; oncology; HIV; and infectious diseases. Its specialty medicines prevent and treat diseases, from human immunodeficiency virus (HIV) to respiratory diseases, immune-mediated conditions like lupus, and cancer. Its vaccine portfolio includes over 20 vaccines to protect people from a range of diseases and infections throughout their lives. General medicines include inhaled medicines for asthma and COPD, antibiotics and medicines for skin diseases. Its portfolio also includes Efimosfermin, a fibroblast growth factor 21 (FGF21) analog therapeutic in clinical development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH).
Financial Summary: BRIEF: For the six months ended 30 June 2025, GSK plc revenues increased 2% to L15.5B. Net income increased 38% to L3.07B. Revenues reflect Europe segment increase of 9% to L3.59B, US segment increase of 2% to L7.87B. Net income benefited from Other segment loss decrease of 49% to L925M, Commercial Operations segment income increase of 3% to L8.03B, Unallocated segment loss decrease of 70% to L42M. Dividend per share increased from L0.30 to L0.32.